Chinese Medical Journal (Jul 2024)

Gallbladder polypoid lesions: Current practices and future prospects

  • Kun Wang,
  • Qingpeng Xu,
  • Lu Xia,
  • Jianing Sun,
  • Kanger Shen,
  • Haoran Liu,
  • Linning Xu,
  • Rui Li,
  • Yuanyuan Ji

DOI
https://doi.org/10.1097/CM9.0000000000003019
Journal volume & issue
Vol. 137, no. 14
pp. 1674 – 1683

Abstract

Read online

Abstract. Gallbladder polypoid lesions (GPLs) refer to any elevated lesion of the mucosal surface of the gallbladder wall, and the prevalence is estimated to be between 0.9% and 12.1%. GPLs include benign polyps and malignant polyps. Benign polyps are further classified as non-neoplastic polyps and neoplastic polyps. Cholesterol polyps are the most common benign polyps and adenocarcinoma is the main type of malignant polyp. Hepatitis B virus infection, liver function abnormalities, dyslipidemia, and obesity are the main risk factors for GPLs. Studies of biological mechanisms have focused on malignant gallbladder polyps, the development of which is regulated by hormone levels in vivo, gut microbiota, inflammation, oxidative stress, Salmonella typhimurium, and related molecules. Diagnostic modalities include chemical examination and imaging examination, with imaging examination currently being the mainstay. Treatment of patients with GPLs is based on the presence or absence of symptoms, age, size of the polyps, tendency of the polyp to increase, and risk factors for symptomatic malignancy to determine whether surgery should be performed.